About Flt3-interacting zinc finger protein 1
Flt3-interacting zinc finger protein 1 (FIZ1) is a protein
from Homo sapiens identified by UniProt accession
Q96SL8, 496 residues long.
MolForge cross-references it against 0 known binders and
6 disease associations.
Target properties
| Protein name | Flt3-interacting zinc finger protein 1 |
|---|
| UniProt accession | Q96SL8 |
|---|
| Gene | FIZ1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 496 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (6)
Diseases linked to this target (Open Targets).
- triglyceride measurement · score 0.20
- red blood cell density measurement · score 0.14
- erythrocyte count · score 0.05
- periodontitis · score 0.00
- mastitis · score 0.00
- hyperprolinemia type 2 · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96SL8-F1 | alphafold | PREDICTED | 61.60 | — |
Amino-acid sequence (496 residues)
MDDVPAPTPA PAPPAAAAPR VPFHCSECGK SFRYRSDLRR HFARHTALKP HACPRCGKGF KHSFNLANHL RSHTGERPYR CSACPKGFRD STGLLHHQVV HTGEKPYCCL VCELRFSSRS SLGRHLKRQH RGVLPSPLQP GPGLPALSAP CSVCCNVGPC SVCGGSGAGG GEGPEGAGAG LGSWGLAEAA AAAAASLPPF ACGACARRFD HGRELAAHWA AHTDVKPFKC PRCERDFNAP ALLERHKLTH DLQGPGAPPA QAWAAGPGAG PETAGEGTAA EAGDAPLASD RRLLLGPAGG GVPKLGGLLP EGGGEAPAPA AAAEPSEDTL YQCDCGTFFA SAAALASHLE AHSGPATYGC GHCGALYAAL AALEEHRRVS HGEGGGEEAA TAAREREPAS GEPPSGSGRG KKIFGCSECE KLFRSPRDLE RHVLVHTGEK PFPCLECGKF FRHECYLKRH RLLHGTERPF PCHICGKGFI TLSNLSRHLK LHRGMD
Explore Flt3-interacting zinc finger protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets